Mice Model Market Size Worth USD 19.36 Billion By 2034
| Report Coverage | Key Statistics |
| Market Size in 2025 | USD 11.43 Billion |
| Market Size in 2026 | USD 12.12 Billion |
| Market Size by 2034 | USD 19.36 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.03% |
| Leading Region in 2024 | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Mice, Technology, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
| Key Market Drivers | Rising prevalence of chronic diseases, increasing R&D in genetics and oncology, and growing use of humanized mice for drug discovery |
| Key Challenges | Ethical concerns regarding animal testing and stringent regulatory frameworks |
| Major Opportunities | Advancements in CRISPR/Cas9 gene-editing technologies and expansion of personalized medicine research |
| Top Companies | Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Janvier Labs, and Envigo |
| Recent Trends | Increased use of humanized mice models, focus on cancer immunotherapy, and collaborations between pharma and research institutions |
Immediate Delivery Available | Buy This Premium Research Report@
Case Study: Advancing Cancer Immunotherapy Through Humanized Mice Models
Background:
Cancer remains one of the most complex and fatal diseases globally, with researchers continuously seeking better preclinical models to study tumor biology and immunotherapy response. Traditional cell-line and xenograft models often fail to replicate the complexity of human immune-tumor interactions, leading to limited translation of preclinical findings to human outcomes.
Challenge:
Pharmaceutical companies and research institutions face difficulties in accurately predicting human immune responses to cancer immunotherapies. Immuno-oncology drugs such as immune checkpoint inhibitors require reliable models that can mimic human immune cell function and tumor microenvironments. Conventional mouse models lack human immune components, leading to poor reproducibility of human results.
Solution - Adoption of Humanized Mice Models:
To overcome these limitations, several research institutions adopted humanized mice models -mice genetically engineered to carry functional human genes, cells, tissues, or organs. One notable case involves The Jackson Laboratory (JAX) and its collaboration with leading oncology researchers to develop NSGTM and NSG-SGM3 mice. These models are engrafted with human hematopoietic stem cells, allowing for the reconstitution of a functional human immune system within the mouse.
Through these models, researchers can observe T-cell activation, tumor-immune interactions, and drug responses that closely resemble those in humans. The humanized mouse model enabled preclinical testing of novel immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, significantly reducing translation gaps between animal and human trials.
Impact:
- Accelerated Drug Development: Pharmaceutical companies using humanized mice observed a 30–40% reduction in the preclinical-to-clinical transition time for immuno-oncology drugs. Improved Predictive Accuracy: These models improved the predictive correlation with human trials by over 60%, enhancing confidence in candidate selection. Broader Applications: Beyond oncology, humanized mice are now widely applied in infectious disease studies, such as HIV and COVID-19 immunopathogenesis, due to their ability to replicate human immune functions.
Key Takeaway:
The integration of humanized mice models represents a paradigm shift in biomedical research. It bridges the translational gap between preclinical and clinical phases, allowing for more accurate modeling of human diseases, immune responses, and drug interactions. This advancement not only drives innovation in cancer immunotherapy but also establishes a framework for next-generation precision medicine research.
Example of Real-World Collaboration:
In 2023, Charles River Laboratories partnered with GenOway to co-develop and distribute new genetically modified mouse lines optimized for immuno-oncology and inflammatory disease studies. This collaboration has allowed global pharmaceutical partners to access customized mouse models faster, enabling better reproducibility and regulatory compliance.
Conclusion:
The success of humanized mice models underscores the future direction of the global mice model market, which continues to evolve with CRISPR gene-editing, AI-driven phenotyping, and contract research outsourcing. As translational medicine expands, such case studies highlight how innovative in vivo platforms can redefine therapeutic development and accelerate the path toward personalized, human-relevant medicine.
Mice Model Market Regional Insights
What is the U.S. Mice Model Market Size and CAGR?
The U.S. mice model market size is calculated at USD 6.94 billion in 2025 and is projected to increase from USD 7.36 billion in 2026 to USD 11.91 billion by 2034, registering a solid CAGR of 6.16% from 2025 to 2034.
How North America Dominated the Mice Model Market?
North America dominated the mouse model market in 2024, the main reason being that it has a solid base of biomedical research and modern healthcare facilities. An increase in the prevalence of chronic diseases, such as cancer, diabetes, and viral infections, among others, has been on the increase in the region, and this has particularly contributed to the demand of having an effective preclinical model, such as laboratory mice.
Drug discovery
Why is Asia Pacific the Fastest-Growing in the Mice Model Market?
Asia Pacific experiences the fastest growth in the market during the forecast period. There has been a surge in the pharmaceutical and biotechnology industry, especially in such countries as China, India, Japan, and South Korea, and this has resulted in a higher requirement for mouse models in drug discovery and preclinical studies. The funding and the government programs in the life sciences research have improved the healthcare infrastructure
In addition, the increasing incidence of chronic illnesses like cancer, diabetes, and cardiovascular diseases is escalating the demand for effective models of the disease. Growing healthcare spending and enthusiasm regarding personalized medicine are also adding to the market growth.
✚ Related Topics You May Find Useful:
➡️ Global Animal Model Market: Explore how preclinical research and drug discovery advancements are driving demand for reliable animal testing models
➡️ Transgenic Animals Market: Examine the growing adoption of genetically engineered animals in biotechnology and pharmaceutical R&D
➡️ Animal Biotechnology Market: Understand how innovations in cloning, genomics, and molecular biology are reshaping veterinary and agricultural sciences
➡️ Pet Care Market: Discover how premiumization and humanization trends are transforming global pet health and nutrition sectors
➡️ Bioinformatics Market: Analyze how AI, big data, and cloud computing are revolutionizing genomic and proteomic research
➡️ Preclinical Imaging Market: Learn how advanced imaging modalities are improving disease modeling and drug efficacy studies
➡️ Genome Editing Market: Track breakthroughs in CRISPR and gene-editing tools fueling advancements in biomedical and agricultural research
➡️ Enzymes Market: See how industrial biotechnology and green chemistry are boosting enzyme applications across multiple sectors
➡️ Gene Therapy Market: Uncover how genetic treatments are reshaping healthcare with curative potential for rare and chronic diseases
➡️ Animal Vaccine Market: Gain insight into the rising focus on livestock immunization and zoonotic disease prevention globally
Mice Model Market Segmentation Insights:
Mice Insights
How did the Inbred Segment Dominate the Mice Model Market?
The inbred segment dominated the market in 2024, which was predominantly used in controlled and reproducible scientific research. The production of inbred mice involves more than 20 generations of brother-sister mating to produce genetically identical members of a particular strain. Such genetic uniformity allows applying them to the modeling of certain human diseases because they lessen experimental variability and increase the credibility of the research findings. Additionally, mice are genetically manipulated in a much easier manner as compared to other animal models, such as rats or rabbits, which makes them very appropriate for in-depth genetic and biomedical research.
The outbred segment is the fastest-growing in the market during the forecast period, due to its benefits in drug testing and translational research. Outbred mice, compared to inbred mice, are more representative of the genetic diversity of human populations and enhance the applicability of preclinical results to patient reactions in practice. Their high fitness, increased body size, and superior performance in reproductive processes also render them more economical in conducting large-scale research. Outbred models have been favored in toxicology and pharmacokinetics studies, as well as behavioral studies, because of their physiological resilience and wider applicability.
Technology Insights
Which Technology Segment Held the Largest Share of the Mice Model Market?
The CRISPR segment held the largest share in the market in 2024. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology allows such easy, effective, and inexpensive genome editing, which is why it is a preferred method when developing advanced mouse models. It can be used to generate somatic genome-edited models, knock-in (KI) and knock-out (KO) germline models, and models specialized to drug treatment experiments.
CRISPR has revolutionized preclinical research because it allows for studying gene functions and disease mechanisms, and can be used in drug discovery and approaches to personalized medicine. Its dominance in the market of mouse models remains determined by its versatility and effectiveness.
The microinjection segment experiences the fastest growth in the market during the forecast period. The technique allows for establishing disease models and examining the functions of genes that are critical to the analysis of human ailments. Microinjection is popular because of its accuracy and consistency with researchers who are interested in producing genetically engineered mice. It is also aided by the increasing need for individual animal models in drug discovery, functional genomics, and biotechnology research.
The microinjection is a critical technology for generating specific mouse models as the complexity of the genetic studies grows, which has given it a fast adoption and market surge.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at ...Mice Model Market Top Companies
- Trans Genic Inc. The Jackson Laboratory Taconic Biosciences, Inc. Sage Labs PolyGene Ozgene Pty Ltd Janvier Labs Inotiv Hera Biolabs Harbour Biomed GenOway S.A. Envigo Cyagen Biosciences Inc. Charles River Laboratories International, Inc. Allentown LLC TransViragen Inc. Aragen Life Sciences Crescendo Biologics Creative Biolabs JOINN Laboratories Co., Ltd. Creative Animodel Applied StemCell Ingenious Targeting Laboratory Vivo Bio Tech Ltd. Marshall BioResources TransCure bioServies JSR Corporation
Industry Leaders Announcement
In January 2024, Roy Cohen, the research assistant professor at the Baker Institute, emphasized that the new mouse model enhances the comprehension of sperm functionality and offers valuable insights into infertility as a problem in humans. This model provides a better avenue to the research of reproductive health issues by providing a better approach to satisfying basic biological interests. Source:
Recent Developments
- In March 2025, Alamar Biosciences launched the NULISAseq Mouse Panel 120, a novel biological marker profiling instrument that has provided the broadest possible protein target coverage of mouse models in the expression analysis. This innovation makes proteomics more precise so that the detection of the disease is possible at an earlier and more accurate stage.
Source:
In December 2023, Biocytogen licensed Neurocrine Biosciences, giving them rights to some of its therapeutic antibodies. The deal involves international development, production, and commercialization, which enhances the competence of both companies in the biologics market.
Source:
In February 2023, Ozgene was selected by the Animal Resources Centre (ARC) to assume its business in Western Australia. Such a transition guarantees further access to genetically tailored mouse and rat lines to satisfy academic and biomedical research in the area.
Source:
Segments Covered in the Report
By Mice
- Inbred Outbred Knockout Hybrid Other Mice
By Technology
- CRISPR Microinjection Embryonic Stem Cell Injection Nuclear Transfer Other Technologies
By Region
- North America Asia Pacific Europe Latin America Middle East & Africa
Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@You can place an order or ask any questions, please feel free to contact at ... | +1 804 441 9344
Stay Ahead with Precedence Research Subscriptions
Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve.
Browse Our Subscription Plans@About Us
Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Web:Our Trusted Data Partners:
Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor Market Stats Insight | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant Specialty Chemicals AnalyticsGet Recent News:
/newsFor the Latest Update Follow Us:
LinkedIn | Medium | Facebook | Twitter
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment